A recent clinical trial compares the use of Drug A to the standard treatment of symptomatic genital herpes. The study involves 10, 000 people with genital herpes who are randomly assigned to receive Drug A or standard treatment. Results of the trial show that the duration of symptoms in patients who received Drug A is 4 days versus 4-5 days in patients who received standard symptomatic measures (p<0.5). The manufacturer of Drug A recommends the use of Drug A in the clinical treatment of genital herpes. Based on the study’s results, which of the following is the most appropriate reason to question the manufacturer’s recommendation? a) The investigators used an inappropriate study design b) It is likely that there was a Type I error c) It is likely that there was Type II error d) The observed difference is not clinically significant e) The observed difference is not statistically significant f) There was insufficient power
A recent clinical trial compares the use of Drug A to the standard treatment of symptomatic genital herpes. The study involves 10, 000 people with genital herpes who are randomly assigned to receive Drug A or standard treatment. Results of the trial show that the duration of symptoms in patients who received Drug A is 4 days versus 4-5 days in patients who received standard symptomatic measures (p<0.5). The manufacturer of Drug A recommends the use of Drug A in the clinical treatment of genital herpes. Based on the study’s results, which of the following is the most appropriate reason to question the manufacturer’s recommendation?
a) The investigators used an inappropriate study design
b) It is likely that there was a Type I error
c) It is likely that there was Type II error
d) The observed difference is not clinically significant
e) The observed difference is not statistically significant
f) There was insufficient power
AI-generated content may present inaccurate or offensive content that does not represent bartleby’s views.
Unlock instant AI solutions
Tap the button
to generate a solution
